I am a
Home I AM A Search Login

Papers of the Week

Papers: 27 Aug 2022 - 2 Sep 2022

Pharmacology/Drug Development

2022 Sep 01

BMC Rheumatol



Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies.


Orbai A-M, Mease PJ, Helliwell PS, FitzGerald O, Fleishaker DL, Mundayat R, Young P
BMC Rheumatol. 2022 Sep 01; 6(1):68.
PMID: 36045453.


Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post-hoc analysis of two phase III studies in patients with PsA treated with tofacitinib assessed dactylitis by location, and the impact on patient-reported outcomes (PROs).